The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer

Anti-Cancer Drugs

Volumn 12, Issue 5, 2001, Pages 387-400

  Mazar, A P ^a  

^a LLC   (United States)

Author keywords

Angiogenesis; Cancer diagnostics; Cancer therapeutics; Metastasis; Urokinase; Urokinase plasminogen activator receptor

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BACTERIAL TOXIN; ENZYME PRECURSOR; GELDANAMYCIN; GENE PRODUCT; HYBRID PROTEIN; INTEGRIN; ISIS 3521; MONOCLONAL ANTIBODY; NAPHTHALENE DERIVATIVE; SCLEROPROTEIN; SERINE PROTEINASE INHIBITOR; SULFONE DERIVATIVE; SURAMIN; SYNTHETIC PEPTIDE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CELL ADHESION; CELL MOTILITY; CLINICAL TRIAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; TUMOR VASCULARIZATION;

HUMANS; NEOPLASMS; PLASMINOGEN ACTIVATORS; RECEPTORS, CELL SURFACE;

EID: 0034933664     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200106000-00001     Document Type: Review

References (114)

1. Urokinase receptor: A molecular organizer in cellular communication
2. The plasminogen activation system in tumor growth, invasion, and metastasis
3. The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis
4. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor 1
5. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor
6. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, and epithelial membrane serine protease
7. Plasma kallikrein/kinin system: A revised hypothesis for its activation and its physiologic contributions
8. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein
9. Overview on fibrinolysis: Plasminogen activation pathways on fibrin and cell surfaces
10. Plasminogen activation by receptor-bound urokinase
11. Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases
12. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin
13. Potential mechanisms for the plasmin-mediated release and activation of latent transforming growth factor-beta1 from the extracellular matrix of growth plate chondrocytes
14. The vascular endothelia growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
15. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases
16. Urokinase receptor is a multifunctional protein: Influence of receptor occupancy on macrophage gene expression
17. Mechanisms of signaling through urokinase receptor and the cellular response
18. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors
19. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers
20. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry
21. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma
22. Expression of urokinase receptor in various stromal-cell populations in human colon cancer: Immunoelectron microscopical analysis
23. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma
24. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases - A comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases
25. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer
26. Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors
27. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer
28. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas
29. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers
30. The urokinase receptor is required for human monocyte chemotaxis in vitro
31. Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility
32. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection
33. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells
34. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways
35. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices
36. Urokinase receptor expression on human microvascular endothelial cells in increased by hypoxia: Implications for capillary-like tube formation in a fibrin matrix
37. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor
38. In vivo angiogenic activity of urokinase: Role of endogenous fibroblast growth factor-2
39. Increased vascular endothelial growth factor in tumor cells and increased production of the receptor for urokinase plasminogen activator in endothelial cells are associated with lymph node metastasis in human breast cancer
40. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers
41. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay
42. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression
43. Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia
44. Upregulation of urokinase receptor expression on migrating endothelial cells
45. A mechanism for modulation of cellular responses to VEGF: Activation of the integrins
46. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor
47. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428
48. Suppression of type I collagenase expression by antisense RNA in melanoma cells results in reduced synthesis of the urokinase-type plasminogen activator receptor
49. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif ( - 152/ - 135) bound with Sp1
50. Targeted disruption of the Kras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis
51. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity
52. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells
53. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells
54. Role of urokinase receptor and caveolin in regulation of integrin signaling
55. FAK integrates growth-factor and integrin signals to promote cell migration
56. Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence
57. The urokinase-type plasminogen activator receptor mediates tyrosine Phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells
58. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins
59. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes
60. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol
61. Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells
62. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: Dependent on extracellular matrix components
63. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes
64. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling
65. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration
66. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function
67. Urokinase receptor (uPAR/CD87) is a ligand for integrins and mediates cell-cell interaction
68. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling
69. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator
70. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis
71. A region in domain II of the urokinase receptor required for urokinase binding
72. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor
73. Identification of the urokinase receptor as an adhesion receptor for vitronectin
74. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect
75. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy
76. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth
77. Prevention of metastasis by inhibition of the urokinase receptor
78. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
79. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist
80. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model
81. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides
82. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display
83. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin
84. Fibroblast growth factors and their inhibitors
85. Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors
86. Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies
87. Regulation of integrin function by the urokinase receptor
88. Anatomy of hot spots in protein interfaces
89. Discovering novel ligands for macromolecules using X-ray crystallographic screening
90. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition
91. Preclinical pharmocologic evaluation of geldanamycin as an antitumor agent
92. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
93. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity
94. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: The loss of wild-type p53 and the hsp90 association
95. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network
96. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase
97. 2 inhibition of hepatocyte growth factor-induced endothelial proliferation and migration
98. Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice
99. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor
100. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
101. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
102. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling
103. Preclinical and clinical studies of MMP inhibitors in cancer
104. An alternatively spliced variant of mRNA for the human receptor of urokinase plasminogen activator
105. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
106. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients
107. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy
108. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis
109. New ELISA for quantitation of human urokinase receptor (CD87) in cancer
110. Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue